An Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 18 Years of Age With Solid Tumours Receiving Chemotherapy

Trial Profile

An Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 18 Years of Age With Solid Tumours Receiving Chemotherapy

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs GSK 1437173A (Primary) ; Antineoplastics
  • Indications Solid tumours; Varicella zoster virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms ZOSTER-028
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Oct 2017 Results presented at the IDWeek 2017.
    • 04 Aug 2016 This trial was completed in Czech Republic (end date: 20-05-2016), according to European Clinical Trials Database.
    • 28 Jul 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top